Werewolf Therapeutics Inc
HOWL1.260USD
+0.100+8.62%
取引時間 （ET）15分遅れの株価
56.48M時価総額
損失額直近12ヶ月PER
詳細情報 Werewolf Therapeutics Inc 企業名
Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with pembrolizumab in multiple solid tumor types. WTX-330 is in development as a single agent in metastatic solid tumors and non-Hodgkin lymphoma. Its pipeline also includes JZP898 and WTX-712.
企業情報
企業コードHOWL
会社名Werewolf Therapeutics Inc
上場日Apr 30, 2021
最高経営責任者「CEO」Dr. Daniel J. (Dan) Hicklin, Ph.D.
従業員数46
証券種類Ordinary Share
決算期末Apr 30
本社所在地200 Talcott Avenue
都市WATERTOWN
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号02472
電話番号16179520555
ウェブサイトhttps://werewolftx.com/
企業コードHOWL
上場日Apr 30, 2021
最高経営責任者「CEO」Dr. Daniel J. (Dan) Hicklin, Ph.D.
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Steven Bloom
Mr. Steven Bloom
Chief Business Officer
Chief Business Officer
--
--
Dr. Michael B. Atkins, M.D.
Dr. Michael B. Atkins, M.D.
Independent Director
Independent Director
--
--
Dr. Daniel J. (Dan) Hicklin, Ph.D.
Dr. Daniel J. (Dan) Hicklin, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Alon Lazarus, Ph.D.
Dr. Alon Lazarus, Ph.D.
Independent Director
Independent Director
--
--
Dr. Meeta Chatterjee, Ph.D.
Dr. Meeta Chatterjee, Ph.D.
Independent Director
Independent Director
--
--
Mr. Briggs W. Morrison, M.D.
Mr. Briggs W. Morrison, M.D.
Director
Director
--
--
Dr. Chulani Karunatilake, Ph.D.
Dr. Chulani Karunatilake, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Michael A. (Mike) Sherman
Mr. Michael A. (Mike) Sherman
Independent Director
Independent Director
--
--
Dr. Luke Evnin, Ph.D.
Dr. Luke Evnin, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Randi Isaacs, M.D.
Dr. Randi Isaacs, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Steven Bloom
Mr. Steven Bloom
Chief Business Officer
Chief Business Officer
--
--
Dr. Michael B. Atkins, M.D.
Dr. Michael B. Atkins, M.D.
Independent Director
Independent Director
--
--
Dr. Daniel J. (Dan) Hicklin, Ph.D.
Dr. Daniel J. (Dan) Hicklin, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Alon Lazarus, Ph.D.
Dr. Alon Lazarus, Ph.D.
Independent Director
Independent Director
--
--
Dr. Meeta Chatterjee, Ph.D.
Dr. Meeta Chatterjee, Ph.D.
Independent Director
Independent Director
--
--
Mr. Briggs W. Morrison, M.D.
Mr. Briggs W. Morrison, M.D.
Director
Director
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Wed, May 14
更新時刻: Wed, May 14
株主統計
種類
株主統計
株主統計
比率
RA Capital Management, LP
14.89%
MPM Capital Inc.
9.60%
PFM Health Sciences, LP
5.59%
MPM BioImpact LLC
5.37%
BofA Global Research (US)
4.69%
Other
59.87%
株主統計
株主統計
比率
RA Capital Management, LP
14.89%
MPM Capital Inc.
9.60%
PFM Health Sciences, LP
5.59%
MPM BioImpact LLC
5.37%
BofA Global Research (US)
4.69%
Other
59.87%
種類
株主統計
比率
Investment Advisor/Hedge Fund
19.93%
Venture Capital
14.89%
Hedge Fund
12.83%
Investment Advisor
9.66%
Research Firm
5.33%
Corporation
4.56%
Individual Investor
1.51%
Bank and Trust
0.08%
Family Office
0.02%
Other
31.19%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
157
30.87M
68.80%
-5.72M
2025Q1
159
30.37M
68.02%
-6.24M
2024Q4
157
31.11M
69.81%
-7.22M
2024Q3
161
35.12M
80.23%
-3.46M
2024Q2
148
35.04M
80.49%
-1.98M
2024Q1
150
35.07M
81.79%
+2.03M
2023Q4
134
30.53M
84.54%
+2.78M
2023Q3
139
30.67M
86.21%
+2.11M
2023Q2
142
30.83M
86.75%
+2.42M
2023Q1
141
30.79M
87.31%
+3.80M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
RA Capital Management, LP
6.68M
14.89%
+536.43K
+8.73%
May 14, 2025
MPM Capital Inc.
4.31M
9.6%
--
--
Apr 14, 2025
PFM Health Sciences, LP
2.51M
5.59%
-398.94K
-13.73%
Mar 31, 2025
MPM BioImpact LLC
2.41M
5.37%
+20.80K
+0.87%
Mar 31, 2025
BofA Global Research (US)
2.10M
4.69%
+24.27K
+1.17%
Mar 31, 2025
Arkin Bio Ventures LP
2.05M
4.56%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
1.51M
3.36%
+88.47K
+6.23%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.48M
3.3%
-29.02K
-1.92%
Mar 31, 2025
Rubric Capital Management LP
1.33M
2.97%
--
--
Mar 31, 2025
Millennium Management LLC
784.62K
1.75%
+188.33K
+31.58%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
DFA Dimensional US Core Equity Market ETF
0%
iShares Micro-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 Growth ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
詳細を見る
DFA Dimensional US Core Equity Market ETF
比率0%
iShares Micro-Cap ETF
比率0%
Avantis US Small Cap Equity ETF
比率0%
iShares Russell 2000 Value ETF
比率0%
iShares Russell 2000 Growth ETF
比率0%
DFA Dimensional US Sustainability Core 1 ETF
比率0%
Dimensional US Core Equity 1 ETF
比率0%
Global X Russell 2000 ETF
比率0%
iShares Russell 2000 ETF
比率0%
Proshares Ultra Russell 2000
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
